Get the Stockscreener App
8.2714
0.60%
-0.0786
89 Bio Inc stock is traded at $8.2714, with a volume of 558.53K.
It is down -0.60% in the last 24 hours and down -22.57% over the past month.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
See More
Previous Close:
$8.35
Open:
$8.66
24h Volume:
558.53K
Relative Volume:
0.27
Market Cap:
$1.23B
Revenue:
-
Net Income/Loss:
$-174.61M
P/E Ratio:
-4.1987
EPS:
-1.97
Net Cash Flow:
$-165.54M
1W Performance:
-0.12%
1M Performance:
-22.57%
6M Performance:
-2.12%
1Y Performance:
-37.64%
1-Day Range:
$8.21
$8.74
1-Week Range:
$6.88
$8.74
52-Week Range:
$5.9857
$13.71
89 Bio Inc Stock (ETNB) Company Profile
Name
89 Bio Inc
Sector
Industry
Phone
(415) 432-9270
Address
142 SANSOME STREET, SAN FRANCISCO, CA
Compare ETNB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ETNB
89 Bio Inc
|
8.27 | 1.23B | 0 | -174.61M | -165.54M | -1.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.82 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.26 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
577.62 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.88 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.54 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
89 Bio Inc Stock (ETNB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Resumed | BofA Securities | Buy |
| Jan-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-10-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-23 | Initiated | UBS | Buy |
| Jun-13-23 | Initiated | Evercore ISI | Outperform |
| May-12-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-20-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-21 | Resumed | Cantor Fitzgerald | Overweight |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-21-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-20 | Initiated | Raymond James | Strong Buy |
| Sep-25-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jul-23-20 | Initiated | BTIG Research | Buy |
| Jul-07-20 | Initiated | Chardan Capital Markets | Buy |
| Dec-09-19 | Initiated | BofA/Merrill | Neutral |
| Dec-09-19 | Initiated | Oppenheimer | Outperform |
| Dec-09-19 | Initiated | RBC Capital Mkts | Outperform |
| Dec-09-19 | Initiated | SVB Leerink | Outperform |
View All
89 Bio Inc Stock (ETNB) Latest News
Citigroup Initiates 89bio Inc at Buy With $25 Price Target -March 13, 2025 at 07:13 am EDT - Marketscreener.com
Time nigh for I&I? Key data points ahead - BioWorld Online
89bio Inc (NASDAQ: ETNB) Is On The Fall - Stocks Register
89bio (NASDAQ:ETNB) Earns Sell (D-) Rating from Weiss Ratings - Defense World
Rhumbline Advisers Has $1.02 Million Stock Position in 89bio, Inc. (NASDAQ:ETNB) - Defense World
89bio FY2025 EPS Forecast Increased by Cantor Fitzgerald - Defense World
Boston Pharma Plays Catch Up To Akero, 89bio In MASH - Citeline News & Insights
Is 89BIO (ETNB) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
New York State Common Retirement Fund Has $128,000 Stake in 89bio, Inc. (NASDAQ:ETNB) - Defense World
89bio to Participate in the Leerink Partners Global Healthcare Conference - The Manila Times
Can 89bio's Liver Disease Pipeline Impress Investors at Upcoming Leerink Conference? - StockTitan
Cantor maintains Overweight on 89bio stock, price target at $29 - Investing.com
Cantor maintains Overweight on 89bio stock, price target at $29 By Investing.com - Investing.com UK
H.C. Wainwright cuts 89bio stock price target to $21, maintains Buy By Investing.com - Investing.com South Africa
H.C. Wainwright cuts 89bio stock price target to $21, maintains Buy - Investing.com
89bio’s (ETNB) “Buy” Rating Reiterated at HC Wainwright - Defense World
89Bio Inc. Faces Financial Risks Amid Market Challenges for Approved Products - MSN
Decoding 89bio Inc (ETNB): A Strategic SWOT Insight - GuruFocus.com
89bio Inc. Advances Clinical Trials Amid Financial Losses - TipRanks
89bio (NASDAQ:ETNB) Stock Price Down 9.1%What's Next? - MarketBeat
89bio (NASDAQ:ETNB) Announces Earnings Results, Misses Estimates By $0.42 EPS - MarketBeat
Cantor Fitzgerald maintains 89bio stock with $29 target By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains 89bio stock with $29 target - Investing.com
89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates - The Globe and Mail
89bio, Inc. SEC 10-K Report - TradingView
89bio Secures $727.5M War Chest While Advancing Critical Phase 3 Trials — What's Next for ETNB? - StockTitan
89bio (ETNB) Projected to Post Earnings on Thursday - Defense World
89bio, Inc. (NASDAQ:ETNB) Receives $31.43 Consensus PT from Brokerages - Defense World
Weiss Ratings Reaffirms "Sell (D-)" Rating for 89bio (NASDAQ:ETNB) - MarketBeat
Cell Sorting Market Size to Hit USD 601.89 Million by 2034 - BioSpace
Wall Street Analysts See a 171.42% Upside in 89BIO (ETNB): Can the Stock Really Move This High? - MSN
89bio, Inc. (NASDAQ:ETNB) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Should You Buy 89BIO (ETNB) After Golden Cross? - Nasdaq
Weiss Ratings Reiterates Sell (D-) Rating for 89bio (NASDAQ:ETNB) - Defense World
89bio Inc (NASDAQ: ETNB) Is A Buzzing Hot Stock - Stocks Register
Biogen Reports Q4 and Full-Year 2024 Results: Strong EPS Growth Amid Revenue Challenges - BSA bureau
89bio, Inc. (NASDAQ:ETNB) Shares Sold by abrdn plc - MarketBeat
89bio (NASDAQ:ETNB) Shares Up 7.1%Time to Buy? - MarketBeat
FY2024 Earnings Estimate for 89bio Issued By Leerink Partnrs - MarketBeat
ETNB89bio, Inc. Latest Stock News & Market Updates - StockTitan
Recent uptick might appease Cabaletta Bio, Inc. (NASDAQ:CABA) institutional owners after losing 89% over the past year - Simply Wall St
Ra Capital Management, L.P. Buys 5,714,285 Shares of 89bio, Inc. (NASDAQ:ETNB) Stock - MarketBeat
89bio Inc [ETNB] stock for 49,999,994 USD was acquired by RA CAPITAL MANAGEMENT, L.P. - Knox Daily
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Inside 89bio's Latest Executive Compensation Move: 163K Share Options Granted - StockTitan
Institutional investors have a lot riding on 89bio, Inc. (NASDAQ:ETNB) with 58% ownership - Yahoo Finance
SG Americas Securities LLC Has $284,000 Stock Position in 89bio, Inc. (NASDAQ:ETNB) - Defense World
Wolfe Research Initiates Coverage on 89bio (NASDAQ:ETNB) - Defense World
What is Leerink Partnrs’ Forecast for 89bio FY2024 Earnings? - Defense World
89bio Inc [ETNB] gain 37.47% so far this year. What now? - The DBT News
89bio Inc (ETNB)’s Market Momentum: Closing Strong at 10.75, Up 15.72 - The Dwinnex
89 Bio Inc Stock (ETNB) Financials Data
Revenue
Net Income
Cash Flow
EPS
89 Bio Inc Stock (ETNB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| McWherter Charles | Director |
Jan 22 '25 |
Buy |
6.71 |
10,000 |
67,100 |
25,000 |
| McWherter Charles | Director |
Jan 21 '25 |
Buy |
6.55 |
5,000 |
32,750 |
15,000 |
| Le-Nguyen Quoc | See Remarks |
Jan 15 '25 |
Sale |
6.49 |
10,963 |
71,150 |
271,833 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):